Wave Life Sciences Ltd. (FRA:1U5)

Market Cap	1.99B +17.2%
Revenue (ttm)	93.10M +103.7%
Net Income	-103.93M
EPS	-0.63
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	123
Open	10.50
Previous Close	10.30
Day's Range	10.50 - 10.50
52-Week Range	4.62 - 17.80
Beta	n/a
RSI	41.98
Earnings Date	Mar 4, 2026

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 288
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1U5

Financial Performance

In 2024, Wave Life Sciences's revenue was $108.30 million, a decrease of -4.42% compared to the previous year's $113.31 million. Losses were -$97.01 million, 68.7% more than in 2023.

Financial numbers in USD